<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95267</article-id><article-id pub-id-type="doi">10.7554/eLife.95267</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.95267.4</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Nicotine enhances the stemness and tumorigenicity in intestinal stem cells via Hippo-YAP/TAZ and Notch signal pathway</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Isotani</surname><given-names>Ryosuke</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Igarashi</surname><given-names>Masaki</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3331-3877</contrib-id><email>migarashi@m.u-tokyo.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Miura</surname><given-names>Masaomi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Naruse</surname><given-names>Kyoko</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kuranami</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Katoh</surname><given-names>Manami</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Nomura</surname><given-names>Seitaro</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yamauchi</surname><given-names>Toshimasa</given-names></name><email>tyamau@m.u-tokyo.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05sj3n476</institution-id><institution>Department of Cardiovascular Medicine, The University of Tokyo Graduate, School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>Department of Frontier Cardiovascular Science, The University of Tokyo, Graduate School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zeng</surname><given-names>Yi Arial</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/034t30j35</institution-id><institution>Chinese Academy of Sciences</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y72wh86</institution-id><institution>Queens University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>03</day><month>01</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP95267</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-01-02"><day>02</day><month>01</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-01-03"><day>03</day><month>01</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.01.02.573853"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-18"><day>18</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95267.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-28"><day>28</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95267.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-11-20"><day>20</day><month>11</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95267.3"/></event></pub-history><permissions><copyright-statement>© 2024, Isotani et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Isotani et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-95267-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-95267-figures-v1.pdf"/><abstract><p>Cigarette smoking is a well-known risk factor inducing the development and progression of various diseases. Nicotine (NIC) is the major constituent of cigarette smoke. However, knowledge of the mechanism underlying the NIC-regulated stem cell functions is limited. In this study, we demonstrate that NIC increases the abundance and proliferative activity of murine intestinal stem cells (ISCs) in vivo and ex vivo. Moreover, NIC induces Yes-associated protein (YAP) /Transcriptional coactivator with PDZ-binding motif (TAZ) and Notch signaling in ISCs via α7-nicotinic acetylcholine receptor (nAchR) and protein kinase C (PKC) activation; this effect was not detected in Paneth cells. The inhibition of Notch signaling by dibenzazepine (DBZ) nullified the effects of NIC on ISCs. NIC enhances in vivo tumor formation from ISCs after loss of the tumor suppressor gene Apc, DBZ inhibited NIC-induced tumor growth. Hence, this study identifies a NIC-triggered pathway regulating the stemness and tumorigenicity of ISCs and suggests the use of DBZ as a potential therapeutic strategy for treating intestinal tumors.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Cigarette smoking is one of the most significant and preventable health risks linked to a variety of diseases, including cancers. Cigarettes release over 5,000 chemicals when they burn, and at least 70 of them cause cancer.</p><p>Nicotine is a highly addictive component of cigarettes. Whilst it is not carcinogenic, it has been shown to affect various properties of many cell types, including stem cells. Stem cells function as a repair system and can be found in many tissues or organs. They can both self-renew and differentiate into specialized cell types. For example, intestinal stem cells (ISCs) are crucial for maintaining the structure of the intestines. However, when dysregulated they can lead to the development of tumors.</p><p>To find out how nicotine affects ISCs in mice, Isotani et al. exposed the animals and ISCs from mice grown in a laboratory to nicotine. Mice were fed 200 μg/ml (which emulates active smoking) for more than 8 weeks in their drinking water. They then used a technique known as immunohistochemistry as well as an organoid forming assay to study the behavior of the cells in the intestine of mice.</p><p>The results showed that exposure to nicotine caused ISCs in the small intestines of the treated mice to divide faster, which increased the number of these cells both in mice and in isolated cells. More specifically, nicotine activated a signaling pathway linked to cell growth, which caused the cells to multiply uncontrollably. When this signaling pathway was experimentally blocked, the ISCs were no longer overactive, and the mice did not develop any tumors.</p><p>In addition, Isotani et al. found that secretory cells, called Paneth cells, which are located near ISCs and have previously been shown to affect the growth rate of ISCs, did not show any changes to these pathways and their cell growth. This suggests that changes to the pathways affecting ISCs are not linked to Paneth cells.</p><p>To develop therapeutic strategies against nicotine-related diseases, including intestinal tumors, it is essential to understand how nicotine influences ISCs behavior. The results highlight the critical role of specific pathways in regulating the growth of ISCs and the formation of intestinal tumors linked to smoking. A next step would be to validate the therapeutic potential of drugs that can inhibit pathways linked to ISC growth.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>intestinal stem cell</kwd><kwd>paneth cell</kwd><kwd>nicotine</kwd><kwd>nAChR</kwd><kwd>Notch</kwd><kwd>YAP/TAZ</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004330</institution-id><institution>Smoking Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Igarashi</surname><given-names>Masaki</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Nicotine affects intestinal stem cells rather than Paneth cells, resulting in the increased stemness and tumorigenicity of intestinal stem cells.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>All tissues and organs are generated from stem cells. Abnormal stem cell functions are significantly associated with age-related organ dysfunction and carcinogenesis (<xref ref-type="bibr" rid="bib1">Adams et al., 2015</xref>). Intestinal epithelial turnover is sustained by intestinal stem cells (ISCs) and adjacent Paneth cells. Paneth cells constitute the niche for ISCs that reside at the bottom of the crypts. Most of the ISCs are leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5) +ones that regulate intestinal homeostasis in response to dietary signals (<xref ref-type="bibr" rid="bib16">Igarashi and Guarente, 2016</xref>; <xref ref-type="bibr" rid="bib38">Yilmaz et al., 2012</xref>). In the intestine, Lgr5 +ISCs are possibly the origin of precancerous adenomas (<xref ref-type="bibr" rid="bib2">Barker et al., 2009</xref>). For instance, long-term high-fat diet (HFD)-induced obesity enhances the self-renewal potential of ISC and promotes in vivo formation of tumors via the induction of peroxisome proliferator-activated receptor delta in ISCs (<xref ref-type="bibr" rid="bib3">Beyaz et al., 2016</xref>).</p><p>Moreover, cigarette smoking has emerged as a potential major risk factor associated with colon cancer, along with metabolic risk factors such as diet and obesity. Previous studies indicate that cigarette smoking is significantly associated with colon cancer and mortality in humans (<xref ref-type="bibr" rid="bib4">Botteri et al., 2008</xref>) and animal models (<xref ref-type="bibr" rid="bib20">Kim et al., 2008</xref>).</p><p>Cigarette smoke contains a wide range of compounds that are harmful to human health; nicotine (NIC) derivatives 4-(methylnitrosamino)–1-(3-pyridyl)–1-butanone (NNK) and N'-nitrosonornicotine (NNN) are highly carcinogenic (<xref ref-type="bibr" rid="bib6">Brunnemann and Hoffmann, 1991</xref>; <xref ref-type="bibr" rid="bib30">Schuller et al., 1995</xref>), which can induce mutations in tumor suppressive genes like <italic>Rasa</italic>, <italic>Trp53</italic>, and <italic>Rb</italic> (<xref ref-type="bibr" rid="bib31">Sekido et al., 2003</xref>). Although NIC itself, the addictive component in cigarette smoke, is generally considered to have a limited ability to initiate cancer, it can stimulate several effects crucial for cancer development independently (<xref ref-type="bibr" rid="bib29">Schaal and Chellappan, 2014</xref>). However, knowledge of the mechanism underlying the NIC-regulated ISC functions and intestinal tumorigenicity is limited.</p><p>In this study, we aimed to demonstrate the effects of NIC treatment on the functions of murine ISCs ex vivo and in vivo. Moreover, we explored the molecular factors and signaling cascades prospectively associated with the regulation of the effects of NIC on ISCs. This study can potentially contribute to the comprehensive knowledge on the pathway by which stem cells respond to NIC, a major component of cigarette smoke, and suggest an effective new strategy for the treatment of smoking-related colon cancer.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>NIC treatment enhances the frequency of ISC in the intestine</title><p>Histological analyses of the small intestine in C57BL/6 mice treated with 200 μg/ml NIC (which emulates active smoking) revealed that NIC exposure decreased villus length without affecting crypt size (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), which was consistent with NIC-induced decrease in the number of differentiated cells, including absorptive enterocytes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>) or chromogranin A+enteroendocrine cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>), in the gut.</p><p>We investigated the effect of NIC on the population of proliferative cells in the crypts using Ki67 labeling to mark proliferative stem and progenitor cells in the crypts. NIC exposure increased abundance of Ki67-positive cells in the small and large intestine (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). Consistently, the number of proliferative olfactomedin-4 (Olfm4)-positive ISCs significantly increased in the small intestine of NIC-treated mice (<xref ref-type="fig" rid="fig1">Figure <ext-link ext-link-type="uri" xlink:href="https://onlinelibrary.wiley.com/doi/full/10.1111/acel.12935#acel12935-fig-0001">1</ext-link>C</xref>). Moreover, the number of LgR5 +colonic stem cells (CSCs) was increased in NIC-treated <italic>Lgr5<sup>-EGFP-IRES-CreERT2</sup></italic> mice expressing EGFP under the control of the <italic>LgR5</italic> promoter (<xref ref-type="fig" rid="fig1">Figure <ext-link ext-link-type="uri" xlink:href="https://onlinelibrary.wiley.com/doi/full/10.1111/acel.12935#acel12935-fig-0001">1</ext-link>D</xref>). Paneth cells support the proliferation of ISCs. However, we did not observe any changes in the number of Paneth cells in NIC-treated mice (<xref ref-type="fig" rid="fig1">Figure <ext-link ext-link-type="uri" xlink:href="https://onlinelibrary.wiley.com/doi/full/10.1111/acel.12935#acel12935-fig-0001">1</ext-link>E</xref>). These results indicate that the self-renewal of ISCs in NIC-treated mice increased with a reciprocal decrease in the number of differentiated cells.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Nicotine (NIC) treatment increases the number of ISCs in the Intestine.</title><p>(<bold>A and B</bold>) Image of Ki67‐positive cells (Red: Ki67, Blue: DAPI) and their quantification at the crypt base of proximal jejunum (<bold>A</bold>) or colon (<bold>B</bold>) of NIC-treated and untreated mice (A:3–4 mice per group, B: 3 mice per group). (<bold>C</bold>) Olfm4 staining image (Red: Olfm4, Blue: DAPI) and the quantification of Olfm4‐positive cells at the crypt base of proximal jejunum with or without NIC treatment (3–4 mice per group). (<bold>D</bold>) GFP staining image (Green: GFP, Blue: DAPI) and the quantification of LgR5-GFP‐positive cells at the crypt base of the colon in NIC or control-treated <italic>Lgr5<sup>-EGFP-IRES-CreERT2</sup></italic> mice (3 mice per group). (<bold>E</bold>) Lysozyme staining image (Red: Lysozyme, Blue: DAPI) and the quantification of Lysozyme‐positive Paneth cells with or without NIC treatment (3–4 mice per group). Original magnifications: 400× (<bold>A–E</bold>). Scale bar: 50 µm (<bold>A–E</bold>). Values represent the mean ± SEM. Significant differences are denoted by p values (Student’s t-test). See also <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>The quantification in immunostaining.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>NIC suppresses the differentiation of ISCs.</title><p>(<bold>A</bold>) Images of the H&amp;E-stained crypt and villus and quantification of their length after or without NIC treatment (3–4 mice per group). (<bold>B</bold>) The quantification of the number of enterocytes per villus in NIC-treated and untreated samples (3 mice per group). (<bold>C</bold>) Chromogranin A staining image (Green: Chromogranin A, Blue: DAPI) and the quantification of Chromogranin A‐positive cells per villus-crypt unit in NIC-treated and untreated samples (3 mice per group). Original magnifications: ×100 (<bold>A</bold>), ×200 (<bold>C</bold>). Scale bar: 100 µm (<bold>A and C</bold>). Values represent the mean ± SEM. Significant differences are denoted by p values (Student’s t-test). See also <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>The quantification in staining.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>NIC treatment enhances the formation of intestinal organoids from ISCs</title><p>Our ISC proliferation analysis using intestinal crypts of wild-type mice revealed that a range of nicotine concentrations (100 nM, 1 µM, and 10 µM) promoted the organoid formation from crypts from the small intestine (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), which was consistent with the in vivo data (<xref ref-type="fig" rid="fig1">Figure 1A and C</xref>). However, the same dose of cotinine, a minor tobacco alkaloid, and a major metabolite of NIC (<xref ref-type="bibr" rid="bib34">Tan et al., 2021</xref>) did not exhibit similar effects (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Furthermore, the addition of 1 µM NIC promoted the organoid formation from colonic crypts (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Next, to address how ISCs and Paneth cells interact functionally, we isolated Lgr5-positive ISCs and Paneth cells from control or NIC-treated <italic>Lgr5<sup>-EGFP-IRES-CreERT2</sup></italic> mice as described previously (<xref ref-type="bibr" rid="bib16">Igarashi and Guarente, 2016</xref>). ISCs and Paneth cells were co-cultured in the culture media containing glycogen synthase kinase 3β (GSK3β) inhibitor CHIR99021, which induces β-catenin and thus stimulates organoid formation (<xref ref-type="bibr" rid="bib16">Igarashi and Guarente, 2016</xref>; <xref ref-type="bibr" rid="bib39">Yin et al., 2014</xref>). Lgr5-positive ISCs isolated from NIC mice formed more organoid colonies than those isolated from control mice when cultured with or without Paneth cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Consistently, the addition of 1 µM NIC to control ISCs stimulated the organoid colony formation (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). However, Paneth cells exhibited no significant difference in function (organoid formation) between control and NIC-treated groups, with or without CHIR99021 (<xref ref-type="fig" rid="fig2">Figure 2</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Therefore, this ex vivo assay for ISC function and ISC–Paneth cell interaction demonstrated that NIC directly stimulates ISC proliferation without affecting the supportive function of Paneth cell for ISC.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>NIC enhances the formation of intestinal organoids from ISCs.</title><p>(<bold>A</bold>) Crypts from the proximal small intestine were cultured with 10 μM, 1 μM, and 100 nM NIC or cotinine to allow ISCs to form organoid colonies; the control set contained no NIC or cotinine. Representative images of the organoids and the quantification of organoids number at day 5 (3 wells/ group) (yellow arrow marks organoids and red arrow indicates aborted crypts). (<bold>B</bold>) Colonic crypts were cultured with or without 1 μM NIC to allow CSCs to form organoid colonies. Representative images of the organoids and the quantification of organoids number at day 5 are shown (3 wells/ group) (yellow arrow marks organoids and red arrow indicates aborted crypts). (<bold>C</bold>) ISCs and Paneth cells were isolated from the small intestine of <italic>Lgr5<sup>‐ EGFP‐IRES‐CreERT2</sup></italic> mice treated with or without NIC; 2×10<sup>3</sup> cells each were co‐cultured in the medium containing 10 μM CHIR99021. Representative images of the organoids and the frequency of organoids at day 5 (3 wells/ group). (<bold>D</bold>) ISCs isolated from the small intestine of <italic>Lgr5<sup>‐EGFP‐IRES‐CreERT2</sup></italic> mice were cultured in the absence of Paneth cells using the medium containing 10 μM CHIR99021, with or without 1 μM NIC. Representative images of the organoids and the frequency of organoids number at day 5 (3 wells/ group). C: control, N: NIC. Original magnification: 40×. Scale bar: 100 µm. Values represent the mean ± SEM. Significant differences are denoted by p values (Student’s t-test). See also <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>The quantification of colonies in organoid assay.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>NIC induces the formation of intestinal organoids from ISCs.</title><p>ISCs and Paneth cells were isolated from the small intestine of <italic>Lgr5<sup>‐EGFP‐IRES‐CreERT2</sup></italic> mice (NIC-treated and untreated); 2×10<sup>3</sup> cells were co-cultured using medium without 10 μM CHIR99021. Representative images of the formed organoids and quantification of the organoid number on day 3 are shown (three wells per group). Values represent the mean ± SEM. Significant differences were denoted by p-values (Student’s t-test). See also <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>The quantification of colonies in organoid assay.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>The α7 subunits of nAChR control the effects of NIC on ISC proliferation</title><p>We investigated the pathway underlying the NIC-regulated proliferation of ISCs. NIC interacts with nicotinic acetylcholine receptors (nAchRs), which are heterodimers of nine types of α subunits (α2–α10) and three types of β subunits (β2– β4)(<xref ref-type="bibr" rid="bib8">Dani, 2015</xref>). We validated the significance of nAChR signal transduction using ISCs, isolated wild-type mice cultured in the presence of NIC, and the nonselective nAChR antagonist Mecamylamine, which indicated that Mecamylamine treatment completely abolishes the NIC-mediated formation of ISC-derived organoids (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We further explored the nAChR subtypes. Considering that NIC has a high affinity for the nAChR comprised of α4 and β2 subunits (<xref ref-type="bibr" rid="bib25">McGranahan et al., 2011</xref>), we cultured ISCs in the presence of NIC and Adiphenine, a non-competitive inhibitor of nAChR (α1, α3β4, α4β2, and α4β4). However, Adiphenine exhibited no effect on the NIC-induced organoid formation from ISCs, indicating that the effect of NIC was not mediated by these nAChRs (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). As some cancer stem cells are known to express α7-nAChR (<xref ref-type="bibr" rid="bib10">Egleton et al., 2008</xref>; <xref ref-type="bibr" rid="bib15">Hirata et al., 2010</xref>), we further analyzed the role of α7-nAChR. The existence of α7-nAChR in ISCs was detected by immunoblotting and RT-PCR, respectively (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>). The higher expression of α7 and α9 subunits in both ISCs and Paneth cells were observed compared with other nAChR subunits. However, there were no significant difference in expression of α7 or α9 subunit between ISCs and Paneth cells (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). To investigate the distribution of nAChRs subunits in human intestine, we analyzed scRNA-seq datasets of the human intestinal epithelium (<xref ref-type="bibr" rid="bib11">Elmentaite et al., 2021</xref>). In consistent with mouse data (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), the expression of human α7 subunit (CHRNA7) is higher than that of other subunits in both ISCs and Paneth cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), although the predominance of the expression in ISCs or Paneth cells was not clear (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The effect of NIC is mediated via the α7 subunits of α7-nicotinic acetylcholine receptor (nAChR).</title><p>(<bold>A</bold>) Isolated ISCs were cultured in a medium with or without 1 μM NIC and 10 μM Mecamylamine (3 wells/group). (<bold>B</bold>) Isolated ISCs were cultured in a medium with or without 1 μM NIC and 3 μM Adiphenine hydrochloride (3 wells/group). (<bold>C</bold>) In ISCs and Paneth cells isolated from control and NIC mice, mRNA levels of nAchR subunits were analyzed using quantitative real-time PCR (n=5 per group; C: control, N: NIC). ∗<italic>p</italic> &lt; 0.05 (vs C STEM) (Student’s t-test). (<bold>D</bold>) ISC or Paneth cell lysates prepared from control and NIC mice were immunoblotted with antibodies against α7-nAchR and β-actin. (<bold>E</bold>) Isolated ISCs were cultured in a medium supplemented with or without 10 μM PNU 282987 (3 wells/group). (<bold>F</bold>) Isolated ISCs were cultured in a medium with or without 1 μM NIC and 1 μM α-Bungarotoxin (3 wells/group). Values represent the mean ± SEM. Significant differences are denoted by p values (Student’s t-test). See also <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Colony quantification and qRT-PCR.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Immunoblotting data with labeling.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95267-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Immunoblotting raw data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95267-fig3-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The distribution of human nAchR subunits in ISCs and Pante cells.</title><p>(<bold>A</bold>) Violin plots for nAchR subunits in ISCs and Panth cells by the analysis of human gut single-cell datasets (<xref ref-type="bibr" rid="bib11">Elmentaite et al., 2021</xref>). (<bold>B</bold>) The number of positive cells for each nAchR in ISCs and Panth cells are shown. See also <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Interestingly, NIC treatment significantly upregulated α7-nAChR in ISCs rather than Paneth cells (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>). Importantly NIC treatment did not induce other nAChR subunits in ISCs (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Moreover, addition of the α7-selective nAChR agonist PNU282987 increased organoid colony formation from ISCs (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), which was consistent with the effects of NIC. Furthermore, α-Bungarotoxin, an α7-selective nAChR antagonist, completely inhibited the NIC-induced increase in organoid formation (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). These outcomes indicate the effect of nicotine is mediated via the α7 subunits of nAChR.</p></sec><sec id="s2-4"><title>NIC induces a Hippo-YAP/TAZ and Notch signaling in ISCs</title><p>As NIC can activate protein kinase C (PKC) or cAMP-dependent protein kinase A (PKA) via α7-nAChR activation (<xref ref-type="bibr" rid="bib15">Hirata et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Dajas-Bailador et al., 2002</xref>), we cultured isolated ISCs in the presence of NIC combined with Gö 6983, a pan-PKC inhibitor, or H89 dihydrochloride, a selective PKA inhibitor. H89 dihydrochloride did not suppress NIC-induced organoid formation, however, Gö 6983 completely abolished this effect of NIC (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). Additionally, we cultured ISCs with NIC and Sotrastaurin, another pan-PKC inhibitor inactive to PKCζ, the loss of which is reported to increase ISC activity both in vivo and in vitro (<xref ref-type="bibr" rid="bib24">Llado et al., 2015</xref>). The observed results with Gö 6983 was reproduced by Sotrastaurin treatment (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>), demonstrating other PKCs than PKCζ mediates the effect of NIC. Consistently, the PKC activator Ingenol-3-angelate stimulated the formation of organoid colonies from ISCs (<xref ref-type="fig" rid="fig5">Figure 5E and F</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>NIC induces Hippo-YAP/TAZ and notch signaling in ISCs.</title><p>(<bold>A and B</bold>) Isolated ISCs cultured using a medium supplemented with or without 1 μM NIC combined with either (<bold>A</bold>) 1 μM H89 dihydrochloride (PKA inhibitor) or (<bold>B</bold>) 10 nM Gö 6983 (PKC inhibitor; 3 wells/group). (<bold>C</bold>) Crypt lysates isolated from control and NIC-treated mice were immunoblotted using antibodies against YAP, TAZ, and β-actin. (<bold>D</bold>) In ISCs or Paneth cells (n=5 per group) isolated from control or NIC mice, mRNA levels of genes associated with Hippo-YAP/TAZ and Notch signaling were determined through quantitative real-time PCR. ∗<italic>p</italic> &lt; 0.05 (vs C STEM) (Student’s t-test). (<bold>E</bold>) Crypt lysates obtained from control and NIC-treated mice were immunoblotted using antibodies against Notch1, Jagged1, Jagged2, Hes5, and β-actin. Values represent the mean ± SEM. Significant differences are denoted by p values (Student’s t-test). See also <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Colony quantification and qRT-PCR.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Immunoblotting data with labeling.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95267-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Immunoblotting raw data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95267-fig4-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>PI3K/AKT, mTORC1, and p38 /MAPK signaling cascades do not mediate the effect of NIC.</title><p>(<bold>A</bold>) Isolated ISCs cultured using a medium supplemented with or without 1 μM NIC combined with 5 nM Sotrastaurin (PKC inhibitor) (3 wells/group). (<bold>B</bold>) Immunoblotting analyses of p38, p-p38, p-S6, or S6 in ISCs isolated from mice treated with vehicle or NIC. (<bold>C</bold>) Isolated ISCs were cultured in a medium with or without 1 μM NIC and 1 μM AKT inhibitor VIII (3 wells/group). (<bold>D</bold>) Isolated ISCs were cultured in a medium with or without 1 μM Nicotine and 5 μM SB 203580 (3 wells/group). (<bold>E</bold>) Isolated ISCs were cultured in a medium with or without 1 μM NIC and 1 μM Rapamycin (3 wells/group). Significant differences are denoted by p values (Student’s t-test). See also <xref ref-type="fig" rid="fig4">Figure 4</xref>.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>The quantification of colonies in organoid assay.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Immunoblotting data with labeling.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95267-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata3"><label>Figure 4—figure supplement 1—source data 3.</label><caption><title>Immunoblotting raw data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95267-fig4-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig4-figsupp1-v1.tif"/></fig></fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Inactivation of Hippo-YAP/TAZ and Notch signaling suppresses NIC-induced Colony Formation in mice.</title><p>(<bold>A</bold>) Isolated ISCs were cultured using a medium with or without 1 μM Nicotine and 5 nM K-975 (3 wells/group). (<bold>B</bold>) Isolated ISCs were cultured using a medium with or without 1 μM Nicotine and 1 μM MK-0752 (3 wells/group). (<bold>C</bold>) Isolated ISCs were cultured using a medium with or without 10 μM PNU282987 and 5 nM K-975 (3 wells/group). (<bold>D</bold>) Isolated ISCs were cultured using a medium with or without 10 μM PNU282987 and 1 μM MK-0752 (3 wells/group). (<bold>E</bold>) Isolated ISCs were cultured in a medium with or without 1 nM<ext-link ext-link-type="uri" xlink:href="https://www.bing.com/ck/a?!&amp;&amp;p=8ea0bca79f25efa3JmltdHM9MTY4ODc3NDQwMCZpZ3VpZD0xODI5M2I5OS02ODg2LTY0MWYtMDg1My0yOWIyNjlmYzY1ZDYmaW5zaWQ9NTI4OA&amp;ptn=3&amp;hsh=3&amp;fclid=18293b99-6886-641f-0853-29b269fc65d6&amp;psq=Ingenol+acetate&amp;u=a1aHR0cHM6Ly93d3cuZnVuYWtvc2hpLmNvLmpwL2NvbnRlbnRzLzUxOTg5&amp;ntb=1"> </ext-link>Ingenol-3-angelate and 5 nM K-975 (3 wells/group). (<bold>F</bold>) Isolated ISCs were cultured in a medium with or without 1 nM Ingenol-3-angelate and 1 μM MK-0752 (3 wells/group). (<bold>G</bold>) Schematic model of NIC-associated signaling pathway in ISCs. The model traces a signaling cascade via α7-nAchR, PKC, Hippo-YAP/TAZ and Notch signaling in ISCs. Values represent the mean ± SEM. Significant differences are denoted by p values (Student’s t-test).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>The quantification of colonies in organoid assay.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig5-v1.tif"/></fig><p>Next, to investigate the possible downstream signaling of α7-nAChR and PKC associated with NIC-induced renewal of ISCs, we explored PI3K/AKT signaling (<xref ref-type="bibr" rid="bib14">Hers et al., 2011</xref>), p38 /mitogen-activated protein kinase (MAPK) signaling (<xref ref-type="bibr" rid="bib27">Rodríguez-Colman et al., 2017</xref>), and mTORC1 signaling (<xref ref-type="bibr" rid="bib16">Igarashi and Guarente, 2016</xref>; <xref ref-type="bibr" rid="bib17">Igarashi et al., 2019</xref>), each of which plays a crucial role in the expansion of ISCs. Results indicate that NIC does not induce these cascades and these were not required for the effects of NIC on ISCs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B–E</xref>).</p><p>YAP/TAZ, the downstream effectors of the Hippo signaling pathway, and Notch receptor 1 (Notch1)/Delta-Like protein 1(Dll1),the main components of Notch signaling are reported to be upregulated in NIC-treated organoids (<xref ref-type="bibr" rid="bib32">Takahashi et al., 2018</xref>). Both the Hippo-YAP/TAZ and Notch signaling pathways regulate intestinal homeostasis via the control of ISC function (<xref ref-type="bibr" rid="bib26">Mo et al., 2014</xref>; <xref ref-type="bibr" rid="bib28">Sancho et al., 2015</xref>) and Notch signaling is positively regulated by YAP/TAZ in the intestine (<xref ref-type="bibr" rid="bib42">Zhou et al., 2011</xref>). Hence, we examined Hippo-YAP/TAZ and Notch signaling. YAP1 and TAZ expression was significantly induced in the crypts of NIC-treated mice (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). <italic>YAP1</italic> and <italic>TAZ</italic> also upregulated at mRNA level in ISCs from NIC mice (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Moreover, activation of Notch signaling in crypts of NIC-treated mice was confirmed through immunoblotting assay (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). The expression of genes, including <italic>Jagged1</italic>, <italic>HeyL, Hes1, Hes5,</italic> and <italic>Dll1</italic>, involved in Notch signaling, significantly increased in ISCs obtained from NIC-treated mice (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Notably, Hippo-YAP/TAZ and Notch signaling were not significantly activated in Paneth cells, indicating that NIC affects α7-nAchR of ISCs rather than Paneth cells.</p><p>Collectively, these results suggest that NIC induces a Hippo-YAP/TAZ and Notch signal pathway in ISCs via activation of α7-nAchR and PKC.</p></sec><sec id="s2-5"><title>Inactivation of Hippo-YAP/TAZ and Notch signaling suppresses the NIC-induced colony formation</title><p>To further explore the role of the Hippo-YAP/TAZ and Notch signaling in NIC-induced ISC expansion, ISCs were cultured with NIC in the presence of either K-975, a specific inhibitor of transcriptional enhanced associate domain (TEAD), which binds to its transcriptional co-activators YAP or TAZ and forms a transcription complex (<xref ref-type="bibr" rid="bib18">Kaneda et al., 2020</xref>), or γ-secretase inhibitor MK-0752 that inhibits the cleavage of Notch into its active signaling effector, Notch intracellular domain (NICD) (<xref ref-type="bibr" rid="bib22">Krop et al., 2012</xref>). Treatment with K-975 and MK-0752 completely abolished the NIC-induced increased organoid formation (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). Furthermore, K-975 or MK-0752 prevented the increase in the organoid formation in ISCs treated with PNU 298987 or Ingenol-3-angelate (<xref ref-type="fig" rid="fig5">Figure 5C–F</xref>), suggesting that YAP/Notch signaling acts downstream of α7-nAchR or PKC leading to the response of ISC to NIC (<xref ref-type="fig" rid="fig5">Figure 5G</xref>).</p></sec><sec id="s2-6"><title>DBZ treatment suppresses the expansion of ISCs by NIC in vivo</title><p>To validate the significance of Notch signaling in the ISC expansion, NIC-treated mice were subjected to daily IP injection of γ-secretase inhibitor dibenzazepine (DBZ) (1 mg/kg body weight) for 2 weeks (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We confirmed that DBZ treatment significantly downregulated Hes5 protein expression in the crypts of NIC-treated mice (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Notably, DBZ suppressed the expression of YAP and TAZ in NIC-treated mice (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). In the intestine, YAP/TAZ regulates Notch signaling (<xref ref-type="bibr" rid="bib42">Zhou et al., 2011</xref>) and Notch activation can activate YAP/TAZ (<xref ref-type="bibr" rid="bib36">Totaro et al., 2018</xref>). Consistent with previous reports, our results demonstrate that Notch inhibitor suppresses YAP/TAZ and Notch activities, indicating a positive feedback loop between Hippo-YAP/TAZ and Notch signaling in ISCs of NIC mice (<xref ref-type="fig" rid="fig5">Figure 5G</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Dibenzazepine (DBZ) treatment suppresses the NIC-induced expansion of ISCs in vivo.</title><p>(<bold>A</bold>) Schematic representation of the treatment showing daily injection of DBZ (1 mg/kg body weight) for 2 weeks. (<bold>B</bold>) Immunoblotting analysis of crypt lysate isolated from DBZ- and vehicle-treated mice in control and NIC-treatment groups using Hes5, YAP, TAZ, and β-actin antibodies. (<bold>C and D</bold>) Immunostained Ki67-positive and (<bold>C</bold>) (Red, Ki67; Blue, DAPI) Olfm4-positive cells (<bold>D</bold>) (Red, Olfm4; blue, DAPI) and their quantification in the proximal jejunum of DBZ- or vehicle-treated mice (NIC-treated and untreated) (n=3 per group). Original magnifications: ×400 (<bold>C and D</bold>). Scale bar: 50 µm (<bold>C and D</bold>). Values represent the mean ± SEM. Significant differences are denoted by p values (Student’s t-test). See also <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>The quantification in immunostaining.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig6-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Immunoblotting data with labeling.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95267-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Immunoblotting raw data.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-95267-fig6-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>DBZ treatment suppresses the NIC-induced expansion of CSCs in vivo.</title><p>(<bold>A and B</bold>) Immuno-stained Ki67-positive cells (<bold>A</bold>) (Red, Ki67; Blue, DAPI) and LgR5-GFP-positive cells (<bold>B</bold>) (Red, Olfm4; blue, DAPI) and quantification of their abundance in the colon of DBZ or vehicle-treated <italic>Lgr5<sup>-EGFP-IRES-CreERT2</sup></italic> mice (NIC-treated and untreated; n=3 per group). Original magnifications: ×400. Scale bar: 50 µm. Values represent the mean ± SEM. Significant differences are denoted by p values (Student’s t-test). See also <xref ref-type="fig" rid="fig6">Figure 6</xref>.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>The quantification in immunostaining.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig6-figsupp1-v1.tif"/></fig></fig-group><p>Ki67 labeling and immunostaining for the ISC marker Olfm4 elucidated the effect of DBZ treatment on the frequency of ISCs in control and NIC-treated mice. DBZ treatment did not alter the population of ISCs in the control mice but significantly suppressed the expansion of Ki67 +and Olfm4 + cells in NIC-treated mice (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>). Moreover, DBZ suppressed the expansion of Ki67 + cells and CSCs in the colon of NIC-treated mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). These outcomes demonstrate that the Hippo-YAP/TAZ and Notch signaling pathways are crucial for ISC expansion in NIC-treated mice analyzed in vivo.</p></sec><sec id="s2-7"><title>DBZ inhibits intestinal tumor growth by NIC</title><p>As ISCs are the potential origin of tumors (<xref ref-type="bibr" rid="bib2">Barker et al., 2009</xref>), we hypothesized that NIC-induced ISC expansion can promote tumor formation in a tumor-initiating background, such as Apc loss. We crossed stem cell-specific <italic>Lgr5<sup>-EGFP-IRES-creERT2</sup></italic> knock-in mice with <italic>Apc<sup>flox/flox</sup></italic> mice (<italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice); in the resulting mice, the transformation of Lgr5–GFP positive stem cells efficiently drives adenoma formation throughout the intestine after Apc loss induced by Cre activation using tamoxifen (<xref ref-type="fig" rid="fig7">Figure 7A</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>BZ inhibits intestinal tumor growth by NIC.</title><p>(<bold>A</bold>) Schematic representation of <italic>Apc<sup>flox/flox</sup>; Lgr5<sup>-EGFP-IRES-CreERT2</sup></italic> (<italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic>)tumor initiation. Mice were treated with control or NIC more than 8 weeks before a single Tamoxifen injection (30 mg/kg body weight), continued for 4 weeks before tissue collection. (<bold>B</bold>) Macroscopic quantification of the number and area of polyps in the entire intestine of control or NIC-treated <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice. (<bold>C</bold>) Representative images (Red: β-catenin, Blue: DAPI) and the quantification of the number of β-catenin positive adenomatous lesions in the entire intestine of control or NIC-treated <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice. (<bold>D</bold>) Schematic presentation of <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> tumor initiation. Control or NIC-treated <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice were subjected to a single Tamoxifen injection (30 mg/kg body weight), followed by daily DBZ or vehicle injections continued for 4 weeks before tissue collection. (<bold>E</bold>) Macroscopic quantification of the number of polyps in the entire intestine of DBZ or vehicle-treated <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice (NIC-treated and untreated). (<bold>F</bold>) Representative images (Red: β-catenin, Blue: DAPI) and the quantification of the number of β-catenin positive adenomatous lesions in the entire intestine of DBZ or vehicle-treated <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice (NIC-treated and untreated). Original magnifications: ×200 (C, and F). Scale bar: 50 µm (C, and F). Values represent the mean ± SEM. Significant differences are denoted by p values (Student’s t-test).</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>The quantification of polyps and β-catenin positive lesions.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-95267-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95267-fig7-v1.tif"/></fig><p>To test whether NIC promotes tumor formation via ISC expansion, tumor formation was induced in NIC-treated <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/f</sup></italic> (NIC- <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic>) mice, and entire intestines, isolated from them, were examined for polyps (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). A marked increase in the abundance of polyps was detected throughout the intestine of NIC-treated <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice; moreover, these polyps were significantly larger than that in the control mice (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Consistently, the area of β-catenin-positive adenomatous lesions throughout the entire intestine significantly increased in NIC- <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). These results indicated that NIC increased the overall polyp burden in the intestines of <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice by increasing their size and number.</p><p>Finally, to validate whether DBZ can suppress NIC-induced intestinal adenomas, we treated NIC- <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice with DBZ 4 weeks after the induction of Apc loss (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Notably, this treatment effectively reduced the abundance of polyps and β-catenin positive adenomatous lesions in NIC- <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup>,</italic> indicating the efficiency of DBZ for the prevention and treatment of NIC-induced intestinal tumors (<xref ref-type="fig" rid="fig7">Figure 7E and F</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our data propose a model in which NIC enhances the self-renewal of ISCs via activated Hippo-YAP/TAZ and Notch signaling (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Our analyses revealed an increase in the number of ISCs in NIC-treated mice. In contrast to ISCs, Paneth cells showed no increase in cell numbers in NIC-treated mice. Similarly, we assessed the functional ability of ISCs and Paneth cells in terms of ex vivo organoid formation, which indicated a NIC-induced gain-of-function in ISCs but not in Paneth cells. Hence, we propose that the increase of ISC activity induced by NIC are not dependent on Paneth cells in functional assays. Furthermore, we traced the signaling pathway in ISCs and detected that ISCs respond to NIC via α7-nAchR, PKC activation, and stimulation of Hippo-YAP/TAZ and Notch signaling (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Consistent with this model, DBZ treatment inhibited Hippo-YAP/TAZ and Notch signaling in mice and prevented NIC-induced ISC expansion and transformation through Apc loss.</p><p>Treatment of organoids with NIC has been reported to enhance cell growth and expression of marker genes of stem cells (<xref ref-type="bibr" rid="bib32">Takahashi et al., 2018</xref>). Moreover, mRNA analysis of NIC-treated organoids showed that the expression of <italic>YAP1/TAZ</italic> and <italic>Notch1/Dll1</italic> was upregulated after treatment with NIC (<xref ref-type="bibr" rid="bib33">Takahashi et al., 2020</xref>). This previous report predicted that NIC activates the Hippo and Notch signaling pathway in Paneth cells rather than ISCs, because the α2β4-nAChR was mainly expressed in Paneth cells (<xref ref-type="bibr" rid="bib33">Takahashi et al., 2020</xref>). However, the hypothesis was not fully testified in the report. In contrast, our analysis validates that NIC affects ISC rather than Panth cells via Hippo-YAP/TAZ and Notch signaling activated though nAchRa7 by mRNA and protein analyses of sorted ISCs or Paneth cells and ex vivo functional assays.</p><p>The crosstalk between Hippo, Notch, and Wnt signaling regulates mammalian intestinal homeostasis (<xref ref-type="bibr" rid="bib36">Totaro et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Khoramjoo et al., 2022</xref>; <xref ref-type="bibr" rid="bib23">Li et al., 2019</xref>). Activated YAP/TAZ, which act downstream of Hippo signaling, translocate to the nucleus and induce the gene expression of Notch receptors and Notch ligands, and thus, Notch is a mediator of YAP1-induced ISC expansion (<xref ref-type="bibr" rid="bib42">Zhou et al., 2011</xref>; <xref ref-type="bibr" rid="bib36">Totaro et al., 2018</xref>). Moreover, YAP/TAZ and Notch signaling congruently induces nuclear translocation of YAP/TAZ and NICD, regulating the expression of common target genes (<xref ref-type="bibr" rid="bib36">Totaro et al., 2018</xref>). Furthermore, YAP with TEADs enhances Jagged1-Notch1 signaling; Notch1 promotes YAP stability through inhibited β-TrCP-mediated degradation and formation of a YAP1- jagged-1/Notch1-positive feedback loop in breast cancer cells (<xref ref-type="bibr" rid="bib41">Zhao et al., 2022</xref>). Similarly, we propose a YAP/TAZ-Notch positive feedback loop in ISCs of NIC-treated mice (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). This model is consistent with DBZ-induced suppression of Hippo-YAP/TAZ and Notch signaling in ISCs from NIC-treated mice (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). As NIC effectively expands the ISC population through the upregulated α7-nAChR and the formation of the YAP/TAZ-Notch loop, we speculate these factors to be good therapeutic targets for treating NIC-induced colon cancer.</p><p>In the intestine, YAP activation enhances the expression of both β-catenin and transcriptional targets of Wnt signaling (<xref ref-type="bibr" rid="bib9">Deng et al., 2018</xref>). Moreover, Notch signaling concomitantly regulates intestinal cell proliferation via Wnt signaling (<xref ref-type="bibr" rid="bib12">Fre et al., 2009</xref>). NIC is supposed to activate Wnt signaling via Hippo-YAP/TAZ and Notch signaling. Similarly, the expression of target proteins (Sox9, TCF4 and, C-myc) of the Wnt/β-catenin pathway as well as cell-cycle regulatory proteins, such as cyclin B, and cyclin E, was up-regulated in crypts obtained from NIC-treated mice in our experiment (data not shown). However, the effect of NIC on ISC organoid formation appears to be independent of CHIR99021, a Wnt activator (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Moreover, In the <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mouse model, APC loss results in a constitutive stabilization of β-catenin, thus the hyperproliferation of ISCs by NIC treatment in this mouse model is likely beyond Wnt activation (<xref ref-type="fig" rid="fig7">Figure 7</xref>). The downstream pathway of Hippo-YAP/TAZ and Notch signaling remains to be determined.</p><p>Our study demonstrated that NIC increased the expression of YAP/TAZ and Notch target genes, as well as the ISC population. Our ex vivo organoid assay revealed the role of Hippo-YAP/TAZ and Notch signaling in NIC-induced ISC expansion. However, the mechanism underlying NIC-activated Hippo-YAP/TAZ and Notch signaling also remains unclear. NIC administration can induce the nuclear translocation and activation of YAP in Esophageal Squamous Cell Cancer (<xref ref-type="bibr" rid="bib40">Zhao et al., 2014</xref>). The nAChRs physically interact with YAP, leading to the upregulation and nuclear translocation of YAP1. This process is considered to be mediated by PKC activation because PKC-specific inhibitors block NIC-induced YAP activation (<xref ref-type="bibr" rid="bib40">Zhao et al., 2014</xref>). Moreover, PKC activity induces the translocation of ADAM-10, which is implicated in the cleavage of Notch receptors (<xref ref-type="bibr" rid="bib5">Bozkulak and Weinmaster, 2009</xref>), to the cell membrane of glioblastoma (<xref ref-type="bibr" rid="bib21">Kohutek et al., 2009</xref>). Hence, we propose the possibility of NIC-induced activation of YAP and ADAM via PKC, leading to Hippo-YAP/TAZ and Notch activation and ISC expansion.</p><p>The lifetime risk of various cancers is strongly correlated with frequency of stem cell divisions that maintain tissue homeostasis (<xref ref-type="bibr" rid="bib35">Tomasetti and Vogelstein, 2015</xref>). However, the risk of cancer associated with stem cell divisions is heavily influenced by both extrinsic and intrinsic factors (<xref ref-type="bibr" rid="bib37">Wu et al., 2016</xref>). Extrinsic factors, such as NIC, may increase the risk of cancer by promoting stem cell division. Our data indicated that NIC increased the abundance and proliferation of ISCs, which may partly explain the increased rate of intestinal tumors in smokers.</p><p>In conclusion, we demonstrated that NIC enhances the ISC population via α7-nAChR as well as Hippo-YAP/TAZ and Notch signaling. These findings revealed the pivotal role of NIC as a stimulant of the cancer stem cell proliferation in intestinal tumors, and thus, explains colon cancer development in cigarette smokers. The development of drugs that can block the α7-nAChR, Hippo-YAP/TAZ, and Notch signaling may provide a new therapeutic strategy for treating colon cancers.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Lgr5<sup>-EGFP-IRES-CreERT2</sup></italic> mice</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">#008875</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Apc CKO</italic> mice</td><td align="left" valign="bottom">National Cancer Institute</td><td align="left" valign="bottom">#01XAA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Rosa26-CAG-lsl-tdTomato</italic> mice</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">#007909</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">rabbit monoclonal anti-Ki67</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#12202</td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">rabbit monoclonal anti-Olfm4</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#39141</td><td align="left" valign="bottom">IHC (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-GFP</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">#sc-9996</td><td align="left" valign="bottom">IHC (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">rabbit polyclonal anti-Lysozyme</td><td align="left" valign="bottom">Thermo Fisher Schientific</td><td align="left" valign="bottom">#PA5-16668</td><td align="left" valign="bottom">IHC (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-chromogranin A</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">#sc-393941</td><td align="left" valign="bottom">IHC (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">rabbit polyclonal anti-β-catenin</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#9562</td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">goat polyclonal anti-mouse IgG H&amp;L (Alexa Fluor 488)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">#ab150113</td><td align="left" valign="bottom">IHC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-β-actin</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-47778</td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-YAP</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-101199</td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-TAZ</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-293183</td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-α7-AchR</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-58607</td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-Notch1</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-376403</td><td align="left" valign="bottom">WB (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-Jagged1</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-390177</td><td align="left" valign="bottom">WB (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-Jagged2</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-515725</td><td align="left" valign="bottom">WB (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-Hes5</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-293445</td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-p38</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-81621</td><td align="left" valign="bottom">WB (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mouse monoclonal anti-phospho-p38</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">#sc-166182</td><td align="left" valign="bottom">WB (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">rabbit monoclonal anti-S6</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">#2217</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">rabbit monoclonal anti-phospho-S6 Ser235/236</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">#4858</td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Mouse IgG, HRP-Linked Whole Ab Sheep</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">NA931</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Rabbit IgG, HRP-Linked Whole Ab Donkey</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">NA934</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">rat monoclonal APC-conjugated anti-mouse CD24 Antibody</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">#101814</td><td align="left" valign="bottom">FCY (1:500)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TSA Plus Cyanine 3 System</td><td align="left" valign="bottom">Akoya Biosciences</td><td align="left" valign="bottom">#NEL744001KT</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Mecamylamine</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">#14602</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Adiphenine hydrochloride</td><td align="left" valign="bottom">MedChemExpress</td><td align="left" valign="bottom">#HY-B0379A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PNU282987</td><td align="left" valign="bottom">MedChemExpress and Cayman Chemical</td><td align="left" valign="bottom">#17424<break/>#HY-12560A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">α-Bungarotoxin</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">#2133/1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">H-89 dihydrochloride</td><td align="left" valign="bottom">MedChemExpress</td><td align="left" valign="bottom">#HY-15979A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Gö 6983</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">#13311</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sotrastaurin</td><td align="left" valign="bottom">MedChemExpress</td><td align="left" valign="bottom">#HY-10343</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">K-975</td><td align="left" valign="bottom">MedChemExpress</td><td align="left" valign="bottom">#HY-138565</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MK-0752</td><td align="left" valign="bottom">MedChemExpress</td><td align="left" valign="bottom">#HY-10974</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ingenol-3-angelate</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">#16207</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">AKT Inhibitor VIII</td><td align="left" valign="bottom">MedChemExpress</td><td align="left" valign="bottom">#HY-10355</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SB203580</td><td align="left" valign="bottom">Tokyo Chemical Industry</td><td align="left" valign="bottom">#F0864</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Rapamycin</td><td align="left" valign="bottom">LKT Laboratories, Inc</td><td align="left" valign="bottom">#R0161</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Collagenase Type IV</td><td align="left" valign="bottom">Worthington Biochemical Corporation</td><td align="left" valign="bottom">#CLS4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Valproic acid sodium salt</td><td align="left" valign="bottom">FUJIFILM Wako Pure Chemical Corporation</td><td align="left" valign="bottom">#2815/100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">[-]-Cotinine</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#C-016</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nicotine hemisulfate salt</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#N1019</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DBZ (Dibenzazepine)</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">#14627</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tamoxifen</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">#13258</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Mounting medium With DAPI Aqueous Fluoroshield</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">#ab104139</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Can Get Signal Immunoreaction Enhancer Solution</td><td align="left" valign="bottom">TOYOBO</td><td align="left" valign="bottom">NKB-101</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p><italic>Lgr5<sup>-EGFP-IRES-CreERT2</sup></italic> mice were purchased from Jackson Laboratory (Bar Harbor, ME). <italic>Apc<sup>flox</sup></italic> mice were obtained from the National Cancer Institute. <italic>Lgr5<sup>-EGFP-IRES-CreERT2</sup></italic> mice were crossed with <italic>Apc<sup>flox/flox</sup></italic> mice (<italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic>). <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup>:tdTomato</italic> mice were generated by crossing <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup></italic> mice with <italic>Rosa26-CAG-lsl-tdTomato</italic> mice from Jackson Laboratories. All lines were maintained in the C57BL/6 background.</p><p>Mice were housed in a controlled environment maintaining 12 hr:12 hr light:dark cycle at 25 ± 1 °C. This study was performed following the guidelines of the Animal Care Committee of the University of Tokyo. All of the animals were handled according to the protocol approved by the Committee on the Ethics of Animal Experiments of the University of Tokyo (Permit Number: A2023M043-04).</p></sec><sec id="s4-2"><title>Nicotine treatment</title><p>Mice were administered with 200 μg/ml NIC (Nicotine hemisulfate salt, Sigma-Aldrich, Saint Louis, MO) through drinking water for more than 8 weeks. Water bottles were replaced every alternate day.</p></sec><sec id="s4-3"><title>Tamoxifen treatment</title><p>Recombination by <italic>Lgr5<sup>CreERT2</sup></italic> in <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup>:tdTomato</italic> mice was induced with a single dose of tamoxifen (30 mg kg<sup>−1</sup> body weight) suspended in corn oil, administered through the intraperitoneal injection. <italic>Lgr5<sup>CreERT2</sup></italic>-induced mice were analyzed 4 weeks after induction.</p></sec><sec id="s4-4"><title>DBZ treatment</title><p>The mice were intraperitoneally injected with DBZ (1 mg/kg body weight; Cayman Chemical, Ann Arbor, MI) or DMSO (in PBS) for 2 or 4 weeks.</p></sec><sec id="s4-5"><title>Crypt isolation and culture</title><p>Crypts were isolated as described previously (<xref ref-type="bibr" rid="bib16">Igarashi and Guarente, 2016</xref>; <xref ref-type="bibr" rid="bib17">Igarashi et al., 2019</xref>). For this purpose, the proximal half of the small intestine was isolated, opened longitudinally, and washed with cold PBS. After washing the intestine with cold PBS, it was cut into small (5 mm long) pieces with scissors and washed using cold PBS. Subsequently, the pieces were gently incubated in PBS supplemented with 5 mM EDTA for 40 min at 4 °C and resuspended in ice-cold PBS without EDTA followed by vigorous shaking performed manually for crypt isolation. Isolated crypts were filtered using a 70 µm mesh (Corning), collected in crypt culture medium, quantified, and embedded in Matrigel (Corning, Inc Corning, NY). In a 48-well plate, 300 isolated crypts were plated per well and cultured using crypt culture medium, Dulbecco’s Modified Eagle Medium:Nutrient Mixture F-12 (DMEM/F12) (Thermo Fisher Scientific) supplemented with 1×N2 (Thermo Fisher Scientific), 1×B27 (Thermo Fisher Scientific), 1 mM N-acetyl-L-cysteine (Sigma-Aldrich), 50 ng/mL EGF (PeproTech, Inc, Cranbury, NJ), 100 ng/mL Noggin (PeproTech, Inc), and R-spondin1 conditioned media (R&amp;D Systems, Minneapolis, MN). The medium was changed in 2 days. Nicotine hemisulphate salt or cotinine ([-]-Cotinine, Sigma-Aldrich) was added to the crypt culture medium as required for the specific analyses. The number of alive organoids was counted under microscope 5 days after plating.</p></sec><sec id="s4-6"><title>Flow cytometry</title><p>ISC and Paneth cells were isolated from dissociated intestinal crypts using flow cytometry as described previously (<xref ref-type="bibr" rid="bib16">Igarashi and Guarente, 2016</xref>; <xref ref-type="bibr" rid="bib17">Igarashi et al., 2019</xref>). The crypts were centrifuged for 5 min at 300×<italic>g</italic> at 4 °C and the pellets were gently resuspended in 800 μl TrypLE Express (Thermo Fisher Scientific) supplemented with 200 μl PBS followed by incubation in a water bath at 32 °C for 1.5 min; after incubation, the samples were placed on ice. Next, 12 mL of cold minimum essential medium (MEM; FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) was added, and the samples were gently triturated twice. After centrifugation for 5 min at 200×<italic>g</italic> at 4 °C, the pellets were resuspended and incubated for 15 min on ice in 0.5 ml MEM containing CD24-APC antibody (1:500, 101814, Biolegend, San Diego, CA). After centrifugation for 5 min at 200×<italic>g</italic> at 4 °C, the pellets were resuspended in MEM containing 1.5 µM propidium iodide (PI) (Fujifilm Wako Pure Chemical Corporation). The samples were filtered through a 40 µm mesh (Corning) and immediately sorted using a BD FACS Aria III Cell Sorter (BD Life Sciences, San Jose, CA). ISCs were isolated as Lgr5-EGFP<sup>hi</sup>CD24<sup>low</sup>PI<sup>-</sup> and Paneth cells were isolated as CD24<sup>hi</sup>SideScatter<sup>hi</sup>Lgr5-EGFP<sup>−</sup>PI<sup>−</sup>.</p></sec><sec id="s4-7"><title>Co-culture of isolated ISCs and Paneth cells</title><p>Isolated ISCs and Paneth cells were suspended separately in the medium containing 1×N2, 1×B27, and 10 μM Y-27632 (FUJIFILM Wako Pure Chemical Corporation). ISCs (2000 cells) and Paneth cells (2000 cells) were then seeded into 30 μl Matrigel containing 1 μM Jagged-1 (AnaSpec, San Jose, CA) and 10 μM Y-27632. The matrigel drops with ISCs and Paneth cells were allowed to solidify on a 48-well plate for 15 minutes in a 37 °C incubator. The culture medium containing 1×N2, 1×B27, 1 mM N-Acetyl-L-cysteine, 50 ng/ml EGF, 200 ng/ml Noggin, R-spondin1 conditioned media (R&amp;D Systems, Minneapolis, MN), and CHIR99021 (FUJIFILM Wako Pure Chemical Corporation) was then added onto the drops of matrigel followed by incubation at 37 °C incubator. Isolated ISCs and Paneth Cells were co-cultured without CHIR99021 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>).</p><p>Other supplements, including Nicotine hemisulfate salt, Mecamylamine (Cayman Chemical), Adiphenine hydrochloride (MedChemExpress), PNU282987(MedChemExpress and Cayman Chemical), α-Bungarotoxin (R&amp;D), H-89 dihydrochloride (MedChemExpress), Gö 6983 (Cayman Chemical), Sotrastaurin (MedChemExpress), K-975 (MedChemExpress), MK-0752 (MedChemExpress), Ingenol-3-angelate (Cayman Chemical), AKT Inhibitor VIII (MedChemExpress), SB203580 (Tokyo Chemical Industry CO., LTD, Tokyo, Japan), and Rapamycin (LKT Laboratories, Inc, St. Paul, MN), was added to the culture medium as needed in different experiments. The absolute values of the organoids are plotted on the y-axis in <xref ref-type="fig" rid="fig2">Figure 2</xref> and S2. The ratio to the control is presented on the y-axis in <xref ref-type="fig" rid="fig3">Figures 3</xref>—<xref ref-type="fig" rid="fig5">5</xref>. The number of colonies with lumens was quantitated on days 3 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) and 5 (<xref ref-type="fig" rid="fig2">Figures 2</xref>—<xref ref-type="fig" rid="fig5">5</xref>) of the culture.</p></sec><sec id="s4-8"><title>Colonic crypt isolation and culture</title><p>Colonic crypts were isolated from the large intestine as described previously with a few modifications23. For this purpose, a 5–7 cm part of the proximal large intestine was isolated, opened longitudinally, and washed with cold PBS. After washing with cold PBS, the intestine was cut into small (5 mm long) pieces with scissors, placed in cold 5 mM EDTA-PBS, and gently rocked for 15 min at 4 °C. After removal of EDTA-PBS, pieces of the intestine were incubated in DMEM/F12 containing 500 U/ml Collagenase Type IV (Worthington Biochemical Corporation, Lakewood, NJ) for 30 min at 37 °C using a water bath. Subsequently, pieces of the intestine were pipetted up and down in cold PBS until most of the crypts were released. The crypt fraction was obtained by passing the suspension through a 70 μm cell strainer followed by centrifuging at 250 × <italic>g</italic> for 5 min. Isolated crypts were collected in a crypt culture medium, counted, and embedded in Matrigel. A total of 1000 crypts were plated per well of a 48-well plate and cultured using a colonic crypt culture medium (DMEM/F12 supplemented by 1xN2, 1xB27, 1 mM N-Acetyl-L-cysteine, 50 ng/ml EGF, 100 ng/ml Noggin, 500 ng/ml R-spondin, 2 mM Valproic acid (FUJIFILM Wako Pure Chemical Corporation), and 10 μM CHIR99021). The medium was replaced in 2 days.</p><p>Nicotine hemisulfate salt was added to the crypt culture medium as needed for experiments. The number of alive spherical organoids formed from the crypts was measured under microscope 5 days after plating them.</p></sec><sec id="s4-9"><title>Investigation of intestinal polyps</title><p>The entire intestine of <italic>Lgr5<sup>CreERT2</sup> Apc<sup>fl/fl</sup>:tdTomato</italic> mice, in which adenomatous polyps were labeled with tdTomato using tamoxifen injection, was promptly excised and cut with the mucosal side up, washed with ice-cold PBS, pinned open on a dissection tray, and fixed using 10% neutral buffered formalin (FUJIFILM Wako Pure Chemical Corporation). The fixed intestine was then photographed, polyps were counted, their diameters were measured using a caliper, and the surface of the polyps was estimated. For the histopathological assay, the entire intestine was fixed on a dry board and gently rolled to form a Swiss roll, which was further used in the immunohistological test.</p></sec><sec id="s4-10"><title>Immunohistochemistry</title><p>Pieces of the proximal jejunum (1–4 cm from the pylorus), proximal colon (1–2 cm from the cecum), and the entire rolled intestine were fixed overnight using 10% neutral-buffered formalin, embedded in paraffin, and sections were prepared. The sections were deparaffinized and subjected to heat-induced antigen retrieval using 10 mM sodium citrate buffer (pH 6.0) in a microwave. Slides were then incubated overnight with the following primary antibodies at 4 °C: rabbit anti-Ki67 (1/200; 12202; Cell Signaling Technology, Danvers, MA), rabbit anti-Olfm4 (1/400; 39141, Cell Signaling Technology), mouse anti-GFP (1/50; sc-9996, Santa Cruz Biotechnology, Dallas, TX), rabbit anti-Lysozyme (1/50; PA5-16668; Thermo Fisher Schientific), mouse anti-chromogranin A (ChgA; 1/50; sc-393941, Santa Cruz Biotechnology), and rabbit anti-β-catenin (1/200; 9562; Cell Signaling). For samples incubated with mouse primary antibodies, Alexa Fluor-conjugated secondary antibody (1/200; ab150113; Abcam, Cambridge, UK) were used, whereas, a TSA Plus Cyanine 3 System (Akoya Biosciences, Marlborough, MA,) was used for rabbit primary antibody treated sets following instructions provided by the manufacturer. Finally, the slides were mounted using Mounting medium With DAPI-Aqueous, Fluoroshield (Abcam, Cambridge, MA). Images were recorded using an all-in-one fluorescence Microscope APEXVIEW APX100 (Olympus,Tokyo, Japan).</p></sec><sec id="s4-11"><title>Quantification</title><p>The lengths of the crypt (from the bottom of the crypt to the crypt-villus junction) and villus (from the crypt-villus junction to the tip of the villus) were measured using ImageJ software. The quantification was repeated for &gt;30 crypt/villus units per mouse. Immuno-stained cells were quantified using randomly selected 50 intact, well-oriented crypts per mouse.</p></sec><sec id="s4-12"><title>Immunoblotting</title><p>The following antibodies, obtained from different sources, were used for immunoblotting: mouse anti-β-actin (sc-47778; Santa Cruz), mouse anti-YAP (Santa Cruz sc-101199), mouse anti-TAZ (Santa Cruz sc-293183), mouse anti-α7-AchR (Santa Cruz sc-58607), mouse anti-Notch1 (Santa Cruz sc-376403), mouse anti-Jagged1 (Santa Cruz sc-390177), mouse anti-Jagged2 (Santa Cruz sc-515725), mouse anti-Hes5 (Santa Cruz sc-293445), mouse anti-p38 (Santa Cruz sc-81621), mouse anti-phospho-p38 (Santa Cruz sc-166182), rabbit anti-S6 (Cell Signaling 2217), and rabbit anti-phospho-S6 Ser235/236 (Cell Signaling 4858). Crypts or sorted cells were lysed using RIPA buffer supplemented with protease and phosphatase inhibitors (Santa Cruz Biotechnology). Subsequently, the protein extracts were denatured by adding SDS loading buffer, boiled, and resolved using SDS-PAGE; immunoblotting was performed using primary antibodies listed above. Mouse IgG (NA931; Cytiva, Tokyo, Japan) and rabbit IgG (NA934; Cytiva) antibodies were used as HRP-conjugated secondary antibodies. The band signals were enhanced using Can Get Signal Immunoreaction Enhancer Solution (TOYOBO CO., LTD., OSAKA, Japan) following the instructions provided by the manufacturer. The band density of all blots was quantified by Image J software.</p></sec><sec id="s4-13"><title>RNA analysis by real-time qPCR</title><p>RNA was extracted from crypts or sorted cells using the RNeasy Plus Mini Kit (QIAGEN, Hilden, Germany). Reverse transcription was performed using ReverTra Ace qPCR RT Master Mix (TOYOBO CO., LTD.). qRT-PCR was performed on a QuantStudio 5 Real-Time PCR System (Applied Biosystems, Waltham, MA) using KAPA SYBR FAST qPCR Master Mix (Kapa Biosystems, Inc, Wilmington, MA). Sequences of the primers used for the Real-Time qPCR are listed below. 18 S rRNA was considered an endogenous reference gene.</p></sec><sec id="s4-14"><title>The list of primers used for real-time qPCR</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Forward primer</th><th align="left" valign="bottom">Reverse Primer</th></tr></thead><tbody><tr><td align="left" valign="bottom">α1</td><td align="left" valign="bottom"><named-content content-type="sequence">TATAACAACGCAGACGGCGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CACAGAGACCGTCATAGGTCC</named-content></td></tr><tr><td align="left" valign="bottom">α2</td><td align="left" valign="bottom"><named-content content-type="sequence">GTGCCCAACACTTCCGATG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TGTAGTCATTCCATTCCTGCTTT</named-content></td></tr><tr><td align="left" valign="bottom">α3</td><td align="left" valign="bottom"><named-content content-type="sequence">CCAGTTTGAGGTGTCTATGTC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TCGGCGTTGTTGTAAAGC</named-content></td></tr><tr><td align="left" valign="bottom">α4</td><td align="left" valign="bottom"><named-content content-type="sequence">CTCAGATGTGGTCCTTGTC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GAGTTCAGATGGGATGCG</named-content></td></tr><tr><td align="left" valign="bottom">α5</td><td align="left" valign="bottom"><named-content content-type="sequence">CATCGTTTTGTTTGATAATGC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TGCGTCCAAGTGACAGTG</named-content></td></tr><tr><td align="left" valign="bottom">α6</td><td align="left" valign="bottom"><named-content content-type="sequence">TGTCTCCGATCCCGTCAC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TTGTTATACAGAACGATGTCAGG</named-content></td></tr><tr><td align="left" valign="bottom">α7</td><td align="left" valign="bottom"><named-content content-type="sequence">GGTCATTTGCCCACTCTG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GACAGCCTATCGGGTGAG</named-content></td></tr><tr><td align="left" valign="bottom">α9</td><td align="left" valign="bottom"><named-content content-type="sequence">ACAAGGCCACCAACTCCA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">ACCAACCCACTCCTCCTCTT</named-content></td></tr><tr><td align="left" valign="bottom">α10</td><td align="left" valign="bottom"><named-content content-type="sequence">TCTGACCTCACAACCCACAA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TCCTGTCTCAGCCTCCATGT</named-content></td></tr><tr><td align="left" valign="bottom">β1</td><td align="left" valign="bottom"><named-content content-type="sequence">AAGCCGAAGGCCAACTGATTA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">TCCTGCCTCTCCTCTCCTTC</named-content></td></tr><tr><td align="left" valign="bottom">β2</td><td align="left" valign="bottom"><named-content content-type="sequence">CCGGCAAGAAGCCGGGACCT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CTCGCTGACACAAGGGCTGCG</named-content></td></tr><tr><td align="left" valign="bottom">β3</td><td align="left" valign="bottom"><named-content content-type="sequence">AAGAAGCAGACTCCTACC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AACAACCTGACTGATGAAG</named-content></td></tr><tr><td align="left" valign="bottom">β4</td><td align="left" valign="bottom"><named-content content-type="sequence">CTACAGGAAGCATTAGAGG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CAGAATACACACAATCACG</named-content></td></tr><tr><td align="left" valign="bottom">Hes1</td><td align="left" valign="bottom"><named-content content-type="sequence">ACACCGGACAAACCAAAGAC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AATGCCGGGAGCTATCTTTC</named-content></td></tr><tr><td align="left" valign="bottom">Hes5</td><td align="left" valign="bottom"><named-content content-type="sequence">GCAGCATAGAGCAGCTGAAG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGGCTTTGCTGTGTTTCAGG</named-content></td></tr><tr><td align="left" valign="bottom">HeyL</td><td align="left" valign="bottom"><named-content content-type="sequence">GTCTTGCAGATGACCGTGGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CTCGGGCATCAAAGAACCCT</named-content></td></tr><tr><td align="left" valign="bottom">Hey1</td><td align="left" valign="bottom"><named-content content-type="sequence">CACCTGAAAATGCTGCACAC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">ATGCTCAGATAACGGGCAAC</named-content></td></tr><tr><td align="left" valign="bottom">Hes1</td><td align="left" valign="bottom"><named-content content-type="sequence">ACACCGGACAAACCAAAGAC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AATGCCGGGAGCTATCTTTC</named-content></td></tr><tr><td align="left" valign="bottom">Jagged1</td><td align="left" valign="bottom"><named-content content-type="sequence">CCTCGGGTCAGTTTGAGCTG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCTTGAGGCACACTTTGAAGTA</named-content></td></tr><tr><td align="left" valign="bottom">Jagged2</td><td align="left" valign="bottom"><named-content content-type="sequence">ACGAGGAGGATGAAGAGCTGA</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GGGGTCTTTGGTGAACTTGTG</named-content></td></tr><tr><td align="left" valign="bottom">YAP</td><td align="left" valign="bottom"><named-content content-type="sequence">CGCTCTTCAATGCCGTCATG</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">AGTCATGGCTTGCTCCCATC</named-content></td></tr><tr><td align="left" valign="bottom">TAZ</td><td align="left" valign="bottom"><named-content content-type="sequence">TCTGTCATGAACCCCAAGCC</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">GGTGGTTCTGTGGACTCAGG</named-content></td></tr><tr><td align="char" char="." valign="bottom">18 S</td><td align="left" valign="bottom"><named-content content-type="sequence">GTAACCCGTTGAACCCCATT</named-content></td><td align="left" valign="bottom"><named-content content-type="sequence">CCATCCAATCGGTAGTAGCG</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s4-15"><title>Single-cell gene expression analysis</title><p>We used single-cell RNA-seq data from the paper 'Cells of the human intestinal tract mapped across space and time' published in Nature (<xref ref-type="bibr" rid="bib11">Elmentaite et al., 2021</xref>) for our analysis. This mapped count data was used as the input for data processing with the Seurat R package (version 5.0.3; <xref ref-type="bibr" rid="bib13">Hao et al., 2024</xref>). We used the ‘FindVariableFeatures’ function to identify highly variable features for downstream analysis. This data was used for dimensionality reduction and cluster detection. We performed linear regression using the ‘ScaleData’ function and a linear dimensionality reduction using the ‘RunPCA’ function. Twenty principal components were used for downstream graph-based, supervised clustering into distinct populations using the ‘FindClusters’ function and uniform manifold approximation, and projection (UMAP) dimensionality reduction was performed to project the cell population onto two dimensions using the ‘RunUMAP’ function. We used this UMAP data to compare CHRNA7 with other receptor subunits and to verify differences in their distribution.</p></sec><sec id="s4-16"><title>Statistical analysis</title><p>All experiment as indicated were performed by at least three independent experiments or technical replicates. Quantitative results are presented as mean ± standard error of the mean. Two groups were compared using unpaired two-tailed Student’s t-test, assuming data normality. p was set at p&lt;0.05 significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Project administration</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Project administration</p></fn><fn fn-type="con" id="con4"><p>Resources</p></fn><fn fn-type="con" id="con5"><p>Resources</p></fn><fn fn-type="con" id="con6"><p>Software, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Supervision, Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Validation</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed following the guidelines of the Animal Care Committee of the University of Tokyo. All of the animals were handled according to the protocol approved by the Committee on the Ethics of Animal Experiments of the University of Tokyo (Permit Number: A2023M043-04).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-95267-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files; source data files have been provided for Figures 1-7, Figure 1-figure supplement 1, Figure 2-figure supplement 1, Figure 4-figure supplement 1 and Figure 6-figure supplement 1.</p></sec><ack id="ack"><title>Acknowledgements</title><p>Flow cytometry was performed in the IMSUT FACS Core laboratory. We acknowledge the IMSUT FACS Core laboratory for assistance with flow cytometry analysis. We thank Dr Yoku Hayakawa (The University of Tokyo) for providing Apc<sup>flox/flox</sup> mouse. Finally, we would like to thank Editage (<ext-link ext-link-type="uri" xlink:href="https://www.editage.com/">https://www.editage.com/</ext-link>) for the English language editing. MI was supported by the Smoking Research Foundation.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Jasper</surname><given-names>H</given-names></name><name><surname>Rudolph</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Aging-induced stem cell mutations as drivers for disease and cancer</article-title><source>Cell Stem Cell</source><volume>16</volume><fpage>601</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.05.002</pub-id><pub-id pub-id-type="pmid">26046760</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Ridgway</surname><given-names>RA</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Begthel</surname><given-names>H</given-names></name><name><surname>van den Born</surname><given-names>M</given-names></name><name><surname>Danenberg</surname><given-names>E</given-names></name><name><surname>Clarke</surname><given-names>AR</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Crypt stem cells as the cells-of-origin of intestinal cancer</article-title><source>Nature</source><volume>457</volume><fpage>608</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1038/nature07602</pub-id><pub-id pub-id-type="pmid">19092804</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyaz</surname><given-names>S</given-names></name><name><surname>Mana</surname><given-names>MD</given-names></name><name><surname>Roper</surname><given-names>J</given-names></name><name><surname>Kedrin</surname><given-names>D</given-names></name><name><surname>Saadatpour</surname><given-names>A</given-names></name><name><surname>Hong</surname><given-names>S-J</given-names></name><name><surname>Bauer-Rowe</surname><given-names>KE</given-names></name><name><surname>Xifaras</surname><given-names>ME</given-names></name><name><surname>Akkad</surname><given-names>A</given-names></name><name><surname>Arias</surname><given-names>E</given-names></name><name><surname>Pinello</surname><given-names>L</given-names></name><name><surname>Katz</surname><given-names>Y</given-names></name><name><surname>Shinagare</surname><given-names>S</given-names></name><name><surname>Abu-Remaileh</surname><given-names>M</given-names></name><name><surname>Mihaylova</surname><given-names>MM</given-names></name><name><surname>Lamming</surname><given-names>DW</given-names></name><name><surname>Dogum</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Bell</surname><given-names>GW</given-names></name><name><surname>Selig</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>GP</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Ferrone</surname><given-names>CR</given-names></name><name><surname>Deshpande</surname><given-names>V</given-names></name><name><surname>Yuan</surname><given-names>G-C</given-names></name><name><surname>Orkin</surname><given-names>SH</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name><name><surname>Yilmaz</surname><given-names>ÖH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>High-fat diet enhances stemness and tumorigenicity of intestinal progenitors</article-title><source>Nature</source><volume>531</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nature17173</pub-id><pub-id pub-id-type="pmid">26935695</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botteri</surname><given-names>E</given-names></name><name><surname>Iodice</surname><given-names>S</given-names></name><name><surname>Bagnardi</surname><given-names>V</given-names></name><name><surname>Raimondi</surname><given-names>S</given-names></name><name><surname>Lowenfels</surname><given-names>AB</given-names></name><name><surname>Maisonneuve</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Smoking and colorectal cancer: a meta-analysis</article-title><source>JAMA</source><volume>300</volume><fpage>2765</fpage><lpage>2778</lpage><pub-id pub-id-type="doi">10.1001/jama.2008.839</pub-id><pub-id pub-id-type="pmid">19088354</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozkulak</surname><given-names>EC</given-names></name><name><surname>Weinmaster</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling</article-title><source>Molecular and Cellular Biology</source><volume>29</volume><fpage>5679</fpage><lpage>5695</lpage><pub-id pub-id-type="doi">10.1128/MCB.00406-09</pub-id><pub-id pub-id-type="pmid">19704010</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunnemann</surname><given-names>KD</given-names></name><name><surname>Hoffmann</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Analytical studies on tobacco-specific N-nitrosamines in tobacco and tobacco smoke</article-title><source>Critical Reviews in Toxicology</source><volume>21</volume><fpage>235</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.3109/10408449109017910</pub-id><pub-id pub-id-type="pmid">2069709</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dajas-Bailador</surname><given-names>FA</given-names></name><name><surname>Soliakov</surname><given-names>L</given-names></name><name><surname>Wonnacott</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Nicotine activates the extracellular signal-regulated kinase 1/2 via the alpha7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones</article-title><source>Journal of Neurochemistry</source><volume>80</volume><fpage>520</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1046/j.0022-3042.2001.00725.x</pub-id><pub-id pub-id-type="pmid">11905997</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dani</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine</article-title><source>International Review of Neurobiology</source><volume>124</volume><fpage>3</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/bs.irn.2015.07.001</pub-id><pub-id pub-id-type="pmid">26472524</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Tan</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>YAP triggers the Wnt/β-catenin signalling pathway and promotes enterocyte self-renewal, regeneration and tumorigenesis after DSS-induced injury</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><elocation-id>153</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-017-0244-8</pub-id><pub-id pub-id-type="pmid">29396428</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egleton</surname><given-names>RD</given-names></name><name><surname>Brown</surname><given-names>KC</given-names></name><name><surname>Dasgupta</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis</article-title><source>Trends in Pharmacological Sciences</source><volume>29</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2007.12.006</pub-id><pub-id pub-id-type="pmid">18262664</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmentaite</surname><given-names>R</given-names></name><name><surname>Kumasaka</surname><given-names>N</given-names></name><name><surname>Roberts</surname><given-names>K</given-names></name><name><surname>Fleming</surname><given-names>A</given-names></name><name><surname>Dann</surname><given-names>E</given-names></name><name><surname>King</surname><given-names>HW</given-names></name><name><surname>Kleshchevnikov</surname><given-names>V</given-names></name><name><surname>Dabrowska</surname><given-names>M</given-names></name><name><surname>Pritchard</surname><given-names>S</given-names></name><name><surname>Bolt</surname><given-names>L</given-names></name><name><surname>Vieira</surname><given-names>SF</given-names></name><name><surname>Mamanova</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Perrone</surname><given-names>F</given-names></name><name><surname>Goh Kai’En</surname><given-names>I</given-names></name><name><surname>Lisgo</surname><given-names>SN</given-names></name><name><surname>Katan</surname><given-names>M</given-names></name><name><surname>Leonard</surname><given-names>S</given-names></name><name><surname>Oliver</surname><given-names>TRW</given-names></name><name><surname>Hook</surname><given-names>CE</given-names></name><name><surname>Nayak</surname><given-names>K</given-names></name><name><surname>Campos</surname><given-names>LS</given-names></name><name><surname>Domínguez Conde</surname><given-names>C</given-names></name><name><surname>Stephenson</surname><given-names>E</given-names></name><name><surname>Engelbert</surname><given-names>J</given-names></name><name><surname>Botting</surname><given-names>RA</given-names></name><name><surname>Polanski</surname><given-names>K</given-names></name><name><surname>van Dongen</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>MD</given-names></name><name><surname>Marioni</surname><given-names>JC</given-names></name><name><surname>Bayraktar</surname><given-names>OA</given-names></name><name><surname>Meyer</surname><given-names>KB</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Barker</surname><given-names>RA</given-names></name><name><surname>Uhlig</surname><given-names>HH</given-names></name><name><surname>Mahbubani</surname><given-names>KT</given-names></name><name><surname>Saeb-Parsy</surname><given-names>K</given-names></name><name><surname>Zilbauer</surname><given-names>M</given-names></name><name><surname>Clatworthy</surname><given-names>MR</given-names></name><name><surname>Haniffa</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>KR</given-names></name><name><surname>Teichmann</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cells of the human intestinal tract mapped across space and time</article-title><source>Nature</source><volume>597</volume><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03852-1</pub-id><pub-id pub-id-type="pmid">34497389</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fre</surname><given-names>S</given-names></name><name><surname>Pallavi</surname><given-names>SK</given-names></name><name><surname>Huyghe</surname><given-names>M</given-names></name><name><surname>Laé</surname><given-names>M</given-names></name><name><surname>Janssen</surname><given-names>KP</given-names></name><name><surname>Robine</surname><given-names>S</given-names></name><name><surname>Artavanis-Tsakonas</surname><given-names>S</given-names></name><name><surname>Louvard</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine</article-title><source>PNAS</source><volume>106</volume><fpage>6309</fpage><lpage>6314</lpage><pub-id pub-id-type="doi">10.1073/pnas.0900427106</pub-id><pub-id pub-id-type="pmid">19251639</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Kowalski</surname><given-names>MH</given-names></name><name><surname>Choudhary</surname><given-names>S</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Hartman</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Molla</surname><given-names>G</given-names></name><name><surname>Madad</surname><given-names>S</given-names></name><name><surname>Fernandez-Granda</surname><given-names>C</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Dictionary learning for integrative, multimodal and scalable single-cell analysis</article-title><source>Nature Biotechnology</source><volume>42</volume><fpage>293</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/s41587-023-01767-y</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hers</surname><given-names>I</given-names></name><name><surname>Vincent</surname><given-names>EE</given-names></name><name><surname>Tavaré</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Akt signalling in health and disease</article-title><source>Cellular Signalling</source><volume>23</volume><fpage>1515</fpage><lpage>1527</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2011.05.004</pub-id><pub-id pub-id-type="pmid">21620960</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>N</given-names></name><name><surname>Sekino</surname><given-names>Y</given-names></name><name><surname>Kanda</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Nicotine increases cancer stem cell population in MCF-7 cells</article-title><source>Biochemical and Biophysical Research Communications</source><volume>403</volume><fpage>138</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.10.134</pub-id><pub-id pub-id-type="pmid">21055391</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Igarashi</surname><given-names>M</given-names></name><name><surname>Guarente</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>mTORC1 and SIRT1 cooperate to foster expansion of gut adult stem cells during calorie restriction</article-title><source>Cell</source><volume>166</volume><fpage>436</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.05.044</pub-id><pub-id pub-id-type="pmid">27345368</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Igarashi</surname><given-names>M</given-names></name><name><surname>Miura</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>E</given-names></name><name><surname>Jaksch</surname><given-names>F</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Guarente</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>NAD<sup>+</sup> supplementation rejuvenates aged gut adult stem cells</article-title><source>Aging Cell</source><volume>18</volume><elocation-id>e12935</elocation-id><pub-id pub-id-type="doi">10.1111/acel.12935</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneda</surname><given-names>A</given-names></name><name><surname>Seike</surname><given-names>T</given-names></name><name><surname>Danjo</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Otsubo</surname><given-names>N</given-names></name><name><surname>Yamaguchi</surname><given-names>D</given-names></name><name><surname>Tsuji</surname><given-names>Y</given-names></name><name><surname>Hamaguchi</surname><given-names>K</given-names></name><name><surname>Yasunaga</surname><given-names>M</given-names></name><name><surname>Nishiya</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>J-I</given-names></name><name><surname>Yatsunami</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Sekido</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma</article-title><source>American Journal of Cancer Research</source><volume>10</volume><fpage>4399</fpage><lpage>4415</lpage><pub-id pub-id-type="pmid">33415007</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoramjoo</surname><given-names>SM</given-names></name><name><surname>Kazemifard</surname><given-names>N</given-names></name><name><surname>Baradaran Ghavami</surname><given-names>S</given-names></name><name><surname>Farmani</surname><given-names>M</given-names></name><name><surname>Shahrokh</surname><given-names>S</given-names></name><name><surname>Asadzadeh Aghdaei</surname><given-names>H</given-names></name><name><surname>Sherkat</surname><given-names>G</given-names></name><name><surname>Zali</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Overview of three proliferation pathways (wnt, notch, and hippo) in intestine and immune system and their role in inflammatory bowel diseases (IBDs)</article-title><source>Frontiers in Medicine</source><volume>9</volume><elocation-id>865131</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2022.865131</pub-id><pub-id pub-id-type="pmid">35677821</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Sugie</surname><given-names>S</given-names></name><name><surname>Yasui</surname><given-names>Y</given-names></name><name><surname>Ishigamori-Suzuki</surname><given-names>R</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Nakagama</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A tobacco-specific carcinogen, NNK, enhances AOM/DSS-induced colon carcinogenesis in male A/J mice</article-title><source>In Vivo</source><volume>22</volume><fpage>557</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">18853746</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohutek</surname><given-names>ZA</given-names></name><name><surname>diPierro</surname><given-names>CG</given-names></name><name><surname>Redpath</surname><given-names>GT</given-names></name><name><surname>Hussaini</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>ADAM-10-mediated N-cadherin cleavage is protein kinase C-alpha dependent and promotes glioblastoma cell migration</article-title><source>The Journal of Neuroscience</source><volume>29</volume><fpage>4605</fpage><lpage>4615</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5126-08.2009</pub-id><pub-id pub-id-type="pmid">19357285</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krop</surname><given-names>I</given-names></name><name><surname>Demuth</surname><given-names>T</given-names></name><name><surname>Guthrie</surname><given-names>T</given-names></name><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Mason</surname><given-names>WP</given-names></name><name><surname>Chinnaiyan</surname><given-names>P</given-names></name><name><surname>Butowski</surname><given-names>N</given-names></name><name><surname>Groves</surname><given-names>MD</given-names></name><name><surname>Kesari</surname><given-names>S</given-names></name><name><surname>Freedman</surname><given-names>SJ</given-names></name><name><surname>Blackman</surname><given-names>S</given-names></name><name><surname>Watters</surname><given-names>J</given-names></name><name><surname>Loboda</surname><given-names>A</given-names></name><name><surname>Podtelezhnikov</surname><given-names>A</given-names></name><name><surname>Lunceford</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Giannotti</surname><given-names>M</given-names></name><name><surname>Hing</surname><given-names>J</given-names></name><name><surname>Beckman</surname><given-names>R</given-names></name><name><surname>LoRusso</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Phase I pharmacologic and pharmacodynamic study of the gamma secretase (notch) inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors</article-title><source>Journal of Clinical Oncology</source><volume>30</volume><fpage>2307</fpage><lpage>2313</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.39.1540</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>N</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Hippo and Wnt signalling pathways: crosstalk during neoplastic progression in gastrointestinal tissue</article-title><source>The FEBS Journal</source><volume>286</volume><fpage>3745</fpage><lpage>3756</lpage><pub-id pub-id-type="doi">10.1111/febs.15017</pub-id><pub-id pub-id-type="pmid">31342636</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llado</surname><given-names>V</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name><name><surname>Duran</surname><given-names>A</given-names></name><name><surname>Reina-Campos</surname><given-names>M</given-names></name><name><surname>Shelton</surname><given-names>PM</given-names></name><name><surname>Linares</surname><given-names>JF</given-names></name><name><surname>Yajima</surname><given-names>T</given-names></name><name><surname>Campos</surname><given-names>A</given-names></name><name><surname>Aza-Blanc</surname><given-names>P</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Diaz-Meco</surname><given-names>MT</given-names></name><name><surname>Moscat</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>repression of intestinal stem cell function and tumorigenesis through direct phosphorylation of β-Catenin and Yap by PKCζ</article-title><source>Cell Reports</source><volume>10</volume><fpage>740</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.007</pub-id><pub-id pub-id-type="pmid">25660024</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGranahan</surname><given-names>TM</given-names></name><name><surname>Patzlaff</surname><given-names>NE</given-names></name><name><surname>Grady</surname><given-names>SR</given-names></name><name><surname>Heinemann</surname><given-names>SF</given-names></name><name><surname>Booker</surname><given-names>TK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>α4β2 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief</article-title><source>The Journal of Neuroscience</source><volume>31</volume><fpage>10891</fpage><lpage>10902</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0937-11.2011</pub-id><pub-id pub-id-type="pmid">21795541</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>HW</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The Hippo signaling pathway in stem cell biology and cancer</article-title><source>EMBO Reports</source><volume>15</volume><fpage>642</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.15252/embr.201438638</pub-id><pub-id pub-id-type="pmid">24825474</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodríguez-Colman</surname><given-names>MJ</given-names></name><name><surname>Schewe</surname><given-names>M</given-names></name><name><surname>Meerlo</surname><given-names>M</given-names></name><name><surname>Stigter</surname><given-names>E</given-names></name><name><surname>Gerrits</surname><given-names>J</given-names></name><name><surname>Pras-Raves</surname><given-names>M</given-names></name><name><surname>Sacchetti</surname><given-names>A</given-names></name><name><surname>Hornsveld</surname><given-names>M</given-names></name><name><surname>Oost</surname><given-names>KC</given-names></name><name><surname>Snippert</surname><given-names>HJ</given-names></name><name><surname>Verhoeven-Duif</surname><given-names>N</given-names></name><name><surname>Fodde</surname><given-names>R</given-names></name><name><surname>Burgering</surname><given-names>BMT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interplay between metabolic identities in the intestinal crypt supports stem cell function</article-title><source>Nature</source><volume>543</volume><fpage>424</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1038/nature21673</pub-id><pub-id pub-id-type="pmid">28273069</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sancho</surname><given-names>R</given-names></name><name><surname>Cremona</surname><given-names>CA</given-names></name><name><surname>Behrens</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Stem cell and progenitor fate in the mammalian intestine: Notch and lateral inhibition in homeostasis and disease</article-title><source>EMBO Reports</source><volume>16</volume><fpage>571</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.15252/embr.201540188</pub-id><pub-id pub-id-type="pmid">25855643</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaal</surname><given-names>C</given-names></name><name><surname>Chellappan</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers</article-title><source>Molecular Cancer Research</source><volume>12</volume><fpage>14</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0541</pub-id><pub-id pub-id-type="pmid">24398389</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuller</surname><given-names>HM</given-names></name><name><surname>McGavin</surname><given-names>MD</given-names></name><name><surname>Orloff</surname><given-names>M</given-names></name><name><surname>Riechert</surname><given-names>A</given-names></name><name><surname>Porter</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Simultaneous exposure to nicotine and hyperoxia causes tumors in hamsters</article-title><source>Lab</source><volume>73</volume><fpage>448</fpage><lpage>456</lpage></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekido</surname><given-names>Y</given-names></name><name><surname>Fong</surname><given-names>KM</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Molecular genetics of lung cancer</article-title><source>Annual Review of Medicine</source><volume>54</volume><fpage>73</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.54.101601.152202</pub-id><pub-id pub-id-type="pmid">12471176</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Shiraishi</surname><given-names>A</given-names></name><name><surname>Murata</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The coordinated activities of nAChR and Wnt signaling regulate intestinal stem cell function in mice</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>738</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19030738</pub-id><pub-id pub-id-type="pmid">29510587</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Shiraishi</surname><given-names>A</given-names></name><name><surname>Osawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Upregulated nicotinic ACh receptor signaling contributes to intestinal stem cell function through activation of Hippo and Notch signaling pathways</article-title><source>International Immunopharmacology</source><volume>88</volume><elocation-id>106984</elocation-id><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106984</pub-id><pub-id pub-id-type="pmid">33182055</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Vrana</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>ZM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cotinine: pharmacologically active metabolite of nicotine and neural mechanisms for its actions</article-title><source>Frontiers in Behavioral Neuroscience</source><volume>15</volume><elocation-id>758252</elocation-id><pub-id pub-id-type="doi">10.3389/fnbeh.2021.758252</pub-id><pub-id pub-id-type="pmid">34744656</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomasetti</surname><given-names>C</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer etiology: variation in cancer risk among tissues can be explained by the number of stem cell divisions</article-title><source>Science</source><volume>347</volume><fpage>78</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1126/science.1260825</pub-id><pub-id pub-id-type="pmid">25554788</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totaro</surname><given-names>A</given-names></name><name><surname>Castellan</surname><given-names>M</given-names></name><name><surname>Di Biagio</surname><given-names>D</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Crosstalk between YAP/TAZ and notch signaling</article-title><source>Trends in Cell Biology</source><volume>28</volume><fpage>560</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2018.03.001</pub-id><pub-id pub-id-type="pmid">29665979</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Powers</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Hannun</surname><given-names>YA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Substantial contribution of extrinsic risk factors to cancer development</article-title><source>Nature</source><volume>529</volume><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/nature16166</pub-id><pub-id pub-id-type="pmid">26675728</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>ÖH</given-names></name><name><surname>Katajisto</surname><given-names>P</given-names></name><name><surname>Lamming</surname><given-names>DW</given-names></name><name><surname>Gültekin</surname><given-names>Y</given-names></name><name><surname>Bauer-Rowe</surname><given-names>KE</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Birsoy</surname><given-names>K</given-names></name><name><surname>Dursun</surname><given-names>A</given-names></name><name><surname>Yilmaz</surname><given-names>VO</given-names></name><name><surname>Selig</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>GP</given-names></name><name><surname>Mino-Kenudson</surname><given-names>M</given-names></name><name><surname>Zukerberg</surname><given-names>LR</given-names></name><name><surname>Bhan</surname><given-names>AK</given-names></name><name><surname>Deshpande</surname><given-names>V</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>mTORC1 in the paneth cell niche couples intestinal stem-cell function to calorie intake</article-title><source>Nature</source><volume>486</volume><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1038/nature11163</pub-id><pub-id pub-id-type="pmid">22722868</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Farin</surname><given-names>HF</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Langer</surname><given-names>R</given-names></name><name><surname>Karp</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny</article-title><source>Nature Methods</source><volume>11</volume><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2737</pub-id><pub-id pub-id-type="pmid">24292484</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nicotine Activates YAP1 through nAChRs mediated signaling in esophageal squamous cell cancer (ESCC)</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e90836</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0090836</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ning</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Shao</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A yes-associated protein 1- Notch1 receptor positive feedback loop promotes breast cancer lung metastasis by attenuating the bone morphogenetic protein 4-SMAD family member 1/5 signaling</article-title><source>Carcinogenesis</source><volume>43</volume><fpage>1162</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgac081</pub-id><pub-id pub-id-type="pmid">36194598</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Barry</surname><given-names>E</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Lawrence</surname><given-names>E</given-names></name><name><surname>Dawson</surname><given-names>D</given-names></name><name><surname>Willis</surname><given-names>JE</given-names></name><name><surname>Markowitz</surname><given-names>SD</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name><name><surname>Avruch</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance</article-title><source>PNAS</source><volume>108</volume><fpage>E1312</fpage><lpage>E1320</lpage><pub-id pub-id-type="doi">10.1073/pnas.1110428108</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95267.4.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Yi Arial</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Chinese Academy of Sciences</institution><country>China</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This study presents a <bold>valuable</bold> finding on a potential signaling pathway responsible for the direct effects of nicotine on intestinal stem cell growth and tumorigenesis. The evidence supporting the claims of the authors is <bold>solid</bold>. This research will be of interest to medical biologists specializing in intestinal tumors.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95267.4.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In their manuscript, authors Isotani et al used in vivo and ex vivo models to show that nicotine could promote stemness and tumorigenicity in murine model. The authors further provided data supporting that the effects of nicotine on stem cell proliferation and tumor initiation were mediated by the Hippo-YAP/TAZ and Notch signal pathway.</p><p>The major strength of this study is the using a set of tools, including Lgr5 reporter mice (Lgr5-EGFP-IRES-CreERT2 mice), stem cell-specific Apc knockout mice (Lgr5CreER Apcfl/fl mice), organoids derived from these mice and chemical compounds (agonists and antagonists) to demonstrate nicotine affects stem cells rather than Paneth cells, leading to increased intestinal stemness and tumorigenicity. Whereas, all models are restricted to mice, lacking analysis of human samples or human intestinal organoids to prove the human relevance of these findings.</p><p>Overall, the presented results support their conclusions. A previous study reported that nicotine acts through the α2β4 nAChR to enhance Wnt production by Paneth cells, which subsequently affects ISCs. In contrast, this manuscript demonstrated that nicotine directly promotes ISCs through α7-nAChR, independent of Paneth cells. Therefore, this manuscript offers novel insights into the mechanism of nicotine's effects on the mouse intestine.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95267.4.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The manuscript by Isotani et al characterizes the hyperproliferation of intestinal stem cells (ISCs) induced by nicotine treatment in vivo. Employing a range of small molecule inhibitors, the authors systematically investigated potential receptors and downstream pathways associated with nicotine-induced phenotypes through in vitro organoid experiments. Notably, the study specifically highlights a signaling cascade involving α7-nAChR/PKC/YAP/TAZ/Notch as a key driver of nicotine-induced stem cell hyperproliferation. Utilizing a Lgr5CreER Apcfl/fl mouse model, the authors extend their findings to propose a potential role of nicotine in stem cell tumorgenesis. The study posits that Notch signaling is essential during this process.</p><p>Strengths and Weaknesses:</p><p>One noteworthy research highlight in this study is the indication, as shown in Figure 2 and S2, that the trophic effect of nicotine on ISC expansion is independent of Paneth cells. In the Discussion section, the authors propose that this independence may be attributed to distinct expression patterns of nAChRs in different cell types. To further substantiate these findings, the authors provided qPCR analysis of nAchRs in ISCs and Paneth cells from isolated whole small intestine, indicating that α7-nAChR uniquely responds to nicotine treatment among various nAChRs. The authors further strengthen the clinical relevance of the study by exploring human scRNA-seq dataset, in which α7-nAChR is indeed also expressed in human ISCs and Paneth cells.</p><p>As shown in the same result section, the effect of nicotine on ISC organoid formation appears to be independent of CHIR99021, a Wnt activator. In the Lgr5CreER Apcfl/fl mouse model, it is known that APC loss results in a constitutive stabilization of β-catenin, thus the hyperproliferation of ISCs by nicotine treatment in this mouse model is likely beyond Wnt activation. The authors have included such discussion.</p><p>In Figure 4, the authors investigate ISC organoid formation with a pan-PKC inhibitor, revealing that PKC inhibition blocks nicotine-induced ISC expansion. It's noteworthy that PKC inhibitors have historically been used successfully to isolate and maintain stem cells by promoting self-renewal. Therefore, it is surprising to observe no or reversal effect on ISCs in this context. The authors have now included an additional PKC inhibitor Sotrastaurin to confirm the role of PKC in nicotine-induced ISC expansion.</p><p>Overall, the manuscript has provided sufficient experimental evidence to address my concerns and also significantly enhanced its quality.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95267.4.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Isotani</surname><given-names>Ryosuke</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Igarashi</surname><given-names>Masaki</given-names></name><role specific-use="author">Author</role><aff><institution>University of Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Miura</surname><given-names>Masaomi</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Naruse</surname><given-names>Kyoko</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Kuranami</surname><given-names>Satoshi</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Katoh</surname><given-names>Manami</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Nomura</surname><given-names>Seitaro</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Yamauchi</surname><given-names>Toshimasa</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Tokyo</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Strengths and weaknesses:</p><p>Although the revised manuscript has significantly improved in the quality of pictures, there seems to be still a discrepancy in Figure 2A: quantification result suggested that NIC (1um) treatment increased the number of colonies from 300 to around 450 (1.5 folds), whereas representative picture shown that the difference was 3 to 12 living organoids (4 folds).</p></disp-quote><p>As reviewer points out, the selected picture was not representative image of “control” group in Figure2A. We replaced it by the new representative image in this revised version.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors</bold>:</p><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>A minor point to be corrected:</p><p>Please consider removing &quot;In consistent with this notion&quot;, which is repetitive with &quot;Similarly&quot;.</p><p>&quot; NIC is supposed to activate Wnt signaling via Hippo-YAP/TAZ and Notch signaling. In consistent with this notion. Similarly, the expression of target proteins (Sox9, TCF4 and, C-myc)...&quot;</p></disp-quote><p>We corrected it according to the reviewer’s suggestion.</p></body></sub-article></article>